Navigation Links
Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
Date:12/10/2009

Laser-type device to be coupled with Stem Cell Therapy in Novel Treatment Approach

San Diego (PRWEB) December 10, 2009 -- Entest Biomedical Inc. (OTCBB: ENTB) and Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) announced they have jointly entered into a letter of intent with Advanced Light Devices to develop a proprietary laser system. It is anticipated this investigational medical device will be used in conjunction Entest’s patent pending adult stem cell therapies for treating patients with Chronic Obstructive Pulmonary Disease (COPD).

The goal of this proposed venture is to produce a laser-based therapeutic platform that increases levels of efficacy of stem cell therapy in patients with COPD. Entest’s patent-pending approach revolves around the use of the patient’s own stem cells in combination with specific laser wavelengths in repairing damaged lung tissue of patients with COPD.

David Koos, President and CEO of Entest Biomedical, stated: “This LOI is the product of our previously announced discussions with manufacturers of laser-based therapies, in which we sought partners whose product portfolios and expertise matched Entest’s needs. By controlling not only the intellectual property on a treatment method, but also the practical administration device itself, we are adding another layer of protection to the approach being developed”

The activities contemplated in the letter of intent are subject to the parties entering into a definitive agreement, which is anticipated to occur shortly. Once such an agreement is reached, schematics, code, and intellectual property pertaining to the new device will be generated and owned by Entest. It is anticipated the laser system will be developed in Bio-Matrix’ Sorrento Mesa facility. This will be the basis for regulatory filings and FDA development of the Entest “regenerative photoceutical” approach to COPD.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
info(at)EntestBio(dot)com
www.EntestBio.com

Follow the Company’s progress on Twitter:

http://twitter.com/Entest_BioMed

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

###

Read the full story at http://www.prweb.com/releases/2009/12/prweb3326934.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
2. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
3. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
4. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
5. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
6. ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum
7. Largest British Fund for Biomedical Research Finances Project on Breakbone Fever in Leuven (K.U.Leuven)
8. Biomedical Research Centre searches for immunological biomarkers
9. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
10. Sponsor-A-Scientist: New Option to Fund Biomedical Research
11. Biomedical Research Centre developing enhanced cells as therapies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment  
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, SEO ... already in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 23, 2017 , ... The Center for Autism and Related ... Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The ... see films in an environment that accommodates their unique needs. , Launched in ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  As National ... In addition, the Company is helping people live ... its customized prescription savings programs in all 50 ... Prescription Assistance Program  and  California Prescription Assistance Program ... from Columbia University for nutritious eating ...
(Date:2/23/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine ... develop and market advanced products and therapies for the ... Dental sectors of healthcare, today announced its record results ... 31, 2016. Full Year 2016 Highlights are: ... over full year 2015 revenue ...
(Date:2/23/2017)... Feb. 23, 2017 LG Innotek today announced that the ... applications. As its sterilization performance is 1.5 times higher than the ... ultraviolet rays in the range of 200 -- 280nm, allowing it to ... by destroying their DNA. LG Innotek,s product emits UV in the ... ...
Breaking Medicine Technology: